Answers are grounded in this paper and cite their sources.
Examines the shift from CAPEX to OPEX models impacting software lifecycle in GxP environments, suggesting implications for operational efficiency.
The pharmaceutical industry is currently navigating a paradigm shift driven by "Pharma 4.0," where the digital transformation of laboratory and production processes is no longer optional. This paper examines the increasing complexity and interdependence of core software systems-specifically ERP (S/4HANA), LIMS, and LES.As software lifecycles shorten, traditional Capital Expenditure (CAPEX) models and rigid Waterfall project management frameworks create significant friction. The paper also explores the financial shift from a Capital Expenditure (CAPEX) to an Operating Expenditure (OPEX) model. This change is presented as a critical factor for maintaining agility, ensuring continuous GxP validation, and effectively avoiding the "Sunk Cost" trap often associated with large-scale digital implementations.
No takes yet. Share an insight, caveat, or question.
Yves Zubler (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: